Experience

Davis Polk advised Tailwind Capital and its portfolio company, Long’s Drugs Inc., in connection with Long’s acquisition of Avita Drugs Inc. Financial terms of the transaction were not…

Davis Polk is advising V. F. Corporation in connection with its $120 million sale of its Contemporary Brands Coalition to Delta Galil Industries Ltd. The transaction, which is subject to…

Davis Polk advised the administrative agent in connection with a $200 million term loan facility (the “Credit Facility”) for Magellan Pharmacy Services, Inc., a wholly owned subsidiary of…

Davis Polk advised FormFactor, Inc. in connection with its acquisition of Cascade Microtech, Inc. pursuant to a merger agreement signed February 3, 2016. The former stockholders of Cascade…

Davis Polk advised Wuxi Construction and Development Investment Company Limited (無錫市建設發展投資有限公司) (the “Company”) in connection with the $300 million 3.25% guaranteed bonds due 2019 (the …

Davis Polk advised McKesson Corporation on its creation of a new health care information technology company, which will combine substantially all of Change Healthcare Holdings, Inc.’s…

Davis Polk advised the joint book-running managers of an SEC-registered offering by co-issuers AmeriGas Partners, L.P. and AmeriGas Finance Corp. of $675 million aggregate principal amount…

Davis Polk is advising Perella Weinberg as financial adviser to HeartWare International, Inc. in connection with its $1.1 billion acquisition by Medtronic plc. Under the terms of the…

Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Universal American Corp. of an aggregate principal amount of $115 million of 4.00% convertible senior…

Davis Polk advised Communications Sales & Leasing, Inc. (“CS&L”) in connection with an underwritten public offering of 14,681,071 shares of common stock of CS&L (the …